Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cytrx Corp (CYTR)

Cytrx Corp (CYTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 10,764
  • Shares Outstanding, K 33,638
  • Annual Sales, $ 250 K
  • Annual Income, $ -12,710 K
  • 60-Month Beta 2.16
  • Price/Sales 44.40
  • Price/Cash Flow N/A
  • Price/Book 0.58
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.35
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/05/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.249 on 03/07/08
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2550 +37.22%
on 06/04/19
0.5698 -38.59%
on 05/28/19
-0.2100 (-37.51%)
since 05/24/19
3-Month
0.2550 +37.22%
on 06/04/19
0.7400 -52.72%
on 03/27/19
-0.3660 (-51.12%)
since 03/26/19
52-Week
0.2550 +37.22%
on 06/04/19
1.2900 -72.88%
on 07/10/18
-0.8501 (-70.84%)
since 06/26/18

Most Recent Stories

More News
CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office...

CYTR : 0.3499 (+9.34%)
CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation

LOS ANGELES , June 26, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued...

CYTR : 0.3499 (+9.34%)
Delisting of Securities of FTD Companies, Inc., Kaixin Auto Holdings (Warrant Only), CytRx Corporation, and Insys Therapeutics, Inc. from The Nasdaq Stock Market

The Nasdaq Stock Market announced today that it will delist the common stock of FTD Companies, Inc. FTD Companies, Inc.'s stock was suspended on June 13, 2019 and has not traded on Nasdaq since that time....

NDAQ : 94.61 (-3.46%)
CYTR : 0.3499 (+9.34%)
CytRx Corporation to Commence Trading on OTCQB Venture Market

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will commence trading on the OTCQB Venture Market as of Tuesday,...

CYTR : 0.3499 (+9.34%)
CytRx Corporation Reports First Quarter 2019 Financial Results

LOS ANGELES , May 15, 2019 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for...

CYTR : 0.3499 (+9.34%)
CytRx Corporation Reports First Quarter 2019 Financial Results

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the first quarter ended March 31, 2019, and provided...

CYTR : 0.3499 (+9.34%)
CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer

LOS ANGELES , May 8, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued...

CYTR : 0.3499 (+9.34%)
CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office...

CYTR : 0.3499 (+9.34%)
CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has provided...

CYTR : 0.3499 (+9.34%)
CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S

LOS ANGELES , May 2, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that arimoclomol...

CYTR : 0.3499 (+9.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade CYTR with:

Key Turning Points

2nd Resistance Point 0.3667
1st Resistance Point 0.3433
Last Price 0.3499
1st Support Level 0.3033
2nd Support Level 0.2867

See More

52-Week High 1.2900
Fibonacci 61.8% 0.8946
Fibonacci 50% 0.7725
Fibonacci 38.2% 0.6504
Last Price 0.3499
52-Week Low 0.2550

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar